Panels
Discover
Changing the status quo
Antibiotic susceptibility testing (AST) hasn’t seen true innovation in over 20+ years. All the while, bacteria have been evolving faster than science, creating resistance to lifesaving antibiotics.
According to the World Health Organization, antibiotic resistance is rising to dangerously high levels, becoming the next global health crisis. Selux is answering this call by creating a revolutionary AST system that outsmarts bacteria.
The global health crisis of antimicrobial resistant infections is a complex and multidimensional problem. The solution is the science and technology of Selux.
To preserve the lifesaving power of antibiotics for future generations we need faster diagnostic results, susceptibility testing on all sample types, testing against all commercially relevant antibiotics at one time, and a commitment to updated FDA and CLSI breakpoints.
Our Solution
Selux is confronting this global health crisis head-on by redefining speed in rapid AST, with our proprietary Next Generation Phenotyping
Comprehensive menu
The Selux rapid NGP System starts with our proprietary 384-well panel. Never before has an AST system been able to break free of panel real estate constraints, until now. This unique design was purposefully created to solve for the need of today’s health crisis of increasing antimicrobial resistance while also preparing for the problems of the future.
Learn More
Rapid AST on all sample types
The Selux NGP System is a true rapid, phenotypic system for all sample types. It can run isolated colonies, in addition to positive blood cultures, all on one system. We use a 384-well panel (gram pos and gram neg) so clinically relevant antibiotics can be tested in parallel. Not to mention this system also has the capacity to run 96 patient samples at once.
Learn More
Latest FDA and CLSI breakpoints
Not having the latest breakpoints can put a patient’s life at risk and contribute to the global health crisis of antimicrobial resistance. The Selux NGP System has the latest FDA and CLSI breakpoints ready for your lab. Plus we're committed to keeping those updated on the Selux system -after all, the burden of breakpoints should rest on us, not you.
Learn More
Redefining patient care and antibiotic stewardship with rapid AST
Despite the importance of antimicrobial susceptibility testing (AST) to infectious diseases patient care, current AST systems either limit result speed, accuracy, or consistency. This forces an overreliance on broad-spectrum antibiotics and contributes to antimicrobial resistance. While multiple rapid AST technologies are under development, these are restricted to bloodstream infections so they cannot address the vast majority of hospitalized patients with other infections. The Selux NGP System offers same shift results, on all sample types.
50%
Of antibiotics used in hospitals are either unnecessary or are prescribed incorrectly.
15
Every 15 minutes someone new dies of an antibiotic-resistant infection.
